CTLA4 and melanoma: A study utilizing the B16-OVA mouse melanoma model demonstrated that the anti-tumor effect of an IL-2/anti-IL-2 complex combined with anti-CTLA-4 mAbs was dependent on both NK cells and CD8+ T cells [101].